Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 170

1.

Ultrastructural, cytogenetic, and molecular findings in mast cell leukemia: Case report.

Bosch-Vilaseca A, Monter-Rovira A, Cisa-Wieczorek S, Oñate G, Bussaglia E, Carricondo M, Remacha Á, Martínez C, Pratcorona M, Blanco ML, Nomdedéu JF.

Clin Case Rep. 2019 Jun 11;7(7):1395-1398. doi: 10.1002/ccr3.2208. eCollection 2019 Jul.

2.

Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.

Ribera J, Zamora L, Morgades M, Vives S, Granada I, Montesinos P, Gómez-Seguí I, Mercadal S, Guàrdia R, Nomdedeu J, Pratcorona M, Tormo M, Martínez-Lopez J, Hernández-Rivas JM, Ciudad J, Orfao A, González-Campos J, Barba P, Escoda L, Esteve J, Genescà E, Solé F, Feliu E, Ribera JM; Spanish PETHEMA Group; Spanish Society of Hematology.

Genes Chromosomes Cancer. 2019 Nov;58(11):815-819. doi: 10.1002/gcc.22788. Epub 2019 Aug 7.

PMID:
31340073
3.

Bone marrow WT1 levels in patients with myeloid neoplasms treated with 5-azacytidine: Identification of responding patients.

Santaliestra M, Garrido A, Carricondo M, Bussaglia E, Pratcorona M, Blanco ML, Gich I, Hoyos M, Esquirol A, García-Cadenas I, Brunet S, Martino R, Sierra J, Nomdedéu JF.

Eur J Haematol. 2019 Sep;103(3):208-214. doi: 10.1111/ejh.13275. Epub 2019 Jul 3.

PMID:
31211880
4.

TET2 missense variants in human neoplasia. A proposal of structural and functional classification.

Bussaglia E, Antón R, Nomdedéu JF, Fuentes-Prior P.

Mol Genet Genomic Med. 2019 Jul;7(7):e00772. doi: 10.1002/mgg3.772. Epub 2019 Jun 11.

5.

ClonoSEQ assay for the detection of lymphoid malignancies.

Monter A, Nomdedéu JF.

Expert Rev Mol Diagn. 2019 Jul;19(7):571-578. doi: 10.1080/14737159.2019.1627877. Epub 2019 Jun 10.

PMID:
31179776
6.

The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients.

Ribera J, Granada I, Morgades M, Vives S, Genescà E, González C, Nomdedeu J, Escoda L, Montesinos P, Mercadal S, Coll R, González-Campos J, Abella E, Barba P, Bermúdez A, Gil C, Tormo M, Pedreño M, Martínez-Carballeira D, Hernández-Rivas JM, Orfao A, Martínez-López J, Esteve J, Bravo P, Garcia-Guiñon A, Debén G, Moraleda JM, Queizán JA, Ortín X, Moreno MJ, Feliu E, Solé F, Ribera JM; PETHEMA Group, Spanish Society of Haematology.

Br J Haematol. 2019 Jul;186(2):263-268. doi: 10.1111/bjh.15887. Epub 2019 Mar 27.

PMID:
30916384
7.

Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia.

Pallarès V, Hoyos M, Chillón MC, Barragán E, Prieto Conde MI, Llop M, Falgàs A, Céspedes MV, Montesinos P, Nomdedeu JF, Brunet S, Sanz MÁ, González-Díaz M, Sierra J, Mangues R, Casanova I.

Cancers (Basel). 2018 Nov 13;10(11). pii: E436. doi: 10.3390/cancers10110436.

8.

CD200 is a useful marker in the diagnosis of chronic lymphocytic leukemia.

Mora A, Bosch R, Cuellar C, Vicente EP, Blanco L, Martino R, Ubeda JM, Sierra J, Moreno C, Nomdedeu J.

Cytometry B Clin Cytom. 2019 Mar;96(2):143-148. doi: 10.1002/cyto.b.21722. Epub 2018 Oct 16.

PMID:
30328261
9.

An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens.

Sobas M, Montesinos P, Boluda B, Bernal T, Vellenga E, Nomdedeu J, González-Campos J, Chillón M, Holowiecka A, Esteve J, Bergua J, González-Sanmiguel JD, Gil-Cortes C, Tormo M, Salamero O, Manso F, Fernández I, de la Serna J, Moreno MJ, Pérez-Encinas M, Krsnik I, Ribera JM, Escoda L, Lowenberg B, Sanz MA; PETHEMA, HOVON, PALG, and GATLA cooperative groups.

Leuk Lymphoma. 2019 Apr;60(4):1030-1035. doi: 10.1080/10428194.2018.1516875. Epub 2018 Oct 15.

PMID:
30322324
10.

Bone marrow mesenchymal stem/stromal cells from risk-stratified acute myeloid leukemia patients are anti-inflammatory in in vivo preclinical models of hematopoietic reconstitution and severe colitis.

de la Guardia RD, Lopez-Millan B, Roca-Ho H, Bueno C, Gutiérrez-Agüera F, Fuster JL, Anguita E, Zanetti SR, Vives S, Nomdedeu J, Sackstein R, Lavoie J, Gónzalez-Rey E, Delgado M, Rosu-Myles M, Menendez P.

Haematologica. 2019 Feb;104(2):e54-e58. doi: 10.3324/haematol.2018.196568. Epub 2018 Sep 20. No abstract available.

11.

A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia.

Onecha E, Linares M, Rapado I, Ruiz-Heredia Y, Martinez-Sanchez P, Cedena T, Pratcorona M, Oteyza JP, Herrera P, Barragan E, Montesinos P, Vela JAG, Magro E, Anguita E, Figuera A, Riaza R, Martinez-Barranco P, Sanchez-Vega B, Nomdedeu J, Gallardo M, Martinez-Lopez J, Ayala R.

Haematologica. 2019 Feb;104(2):288-296. doi: 10.3324/haematol.2018.194712. Epub 2018 Aug 9.

12.

Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia.

Genescà E, Lazarenkov A, Morgades M, Berbis G, Ruíz-Xivillé N, Gómez-Marzo P, Ribera J, Juncà J, González-Pérez A, Mercadal S, Guardia R, Artola MT, Moreno MJ, Martínez-López J, Zamora L, Barba P, Gil C, Tormo M, Cladera A, Novo A, Pratcorona M, Nomdedeu J, González-Campos J, Almeida M, Cervera J, Montesinos P, Batlle M, Vives S, Esteve J, Feliu E, Solé F, Orfao A, Ribera JM.

J Hematol Oncol. 2018 Jul 24;11(1):96. doi: 10.1186/s13045-018-0639-8.

13.

Chronic Lymphocytic Leukemia: Clinical Stages Maintain Their Prognostic Significance Over the Course of the Disease and Are Surrogates for Response to Therapy.

Vicente EP, Cuellar-García C, Martinez M, Soler A, Mora A, Bosch R, Brunet S, Briones J, García I, Esquirol A, Granell M, Saavedra S, Nomdedeu J, Sierra J, Martino R, Moreno C.

Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):737-742. doi: 10.1016/j.clml.2018.06.023. Epub 2018 Jun 27.

PMID:
30017595
14.

A 4-gene expression prognostic signature might guide post-remission therapy in patients with intermediate-risk cytogenetic acute myeloid leukemia.

Torrebadell M, Díaz-Beyá M, Kalko SG, Pratcorona M, Nomdedeu J, Navarro A, Gel B, Brunet S, Sierra J, Camós M, Esteve J.

Leuk Lymphoma. 2018 Oct;59(10):2394-2404. doi: 10.1080/10428194.2017.1422859. Epub 2018 Feb 2.

PMID:
29390924
15.

Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival.

Guillem V, Calabuig M, Brunet S, Esteve J, Escoda L, Gallardo D, Ribera JM, Queipo de Llano MP, Arnan M, Pedro C, Amigo ML, Martí-Tutusaus JM, García-Guiñón A, Bargay J, Sampol A, Salamero O, Font L, Talarn C, Hoyos M, Díaz-Beyá M, Garrido A, Navarro B, Nomdédeu J, Sierra J, Tormo M.

Leuk Lymphoma. 2018 Oct;59(10):2383-2393. doi: 10.1080/10428194.2017.1422858. Epub 2018 Jan 18.

PMID:
29345176
16.

Outcomes of GatekeeperTM prosthesis implantation for the treatment of fecal incontinence: a multicenter observational study.

Trenti L, Biondo S, Noguerales F, Nomdedeu J, Coret A, Scherer R, Fraccalvieri D, Frago R, Kreisler E.

Tech Coloproctol. 2017 Dec;21(12):963-970. doi: 10.1007/s10151-017-1723-8. Epub 2017 Nov 20.

PMID:
29159781
17.

NEDD9, an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients.

Pallarès V, Hoyos M, Chillón MC, Barragán E, Conde MIP, Llop M, Céspedes MV, Nomdedeu JF, Brunet S, Sanz MÁ, González-Díaz M, Sierra J, Casanova I, Mangues R.

Oncotarget. 2017 Jun 16;8(44):76003-76014. doi: 10.18632/oncotarget.18537. eCollection 2017 Sep 29.

18.

Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project.

Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P, McIver-Brown N, Villamor N, Psarra K, Arroz M, Milani R, de la Serna J, Cedena MT, Jaksic O, Nomdedeu J, Moreno C, Rigolin GM, Cuneo A, Johansen P, Johnsen HE, Rosenquist R, Niemann CU, Kern W, Westerman D, Trneny M, Mulligan S, Doubek M, Pospisilova S, Hillmen P, Oscier D, Hallek M, Ghia P, Montserrat E.

Cytometry B Clin Cytom. 2018 Jan;94(1):121-128. doi: 10.1002/cyto.b.21595. Epub 2018 Jan 17.

19.

Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value.

Nomdedéu JF, Esquirol A, Carricondo M, Pratcorona M, Hoyos M, Garrido A, Rubio M, Bussaglia E, García-Cadenas I, Estivill C, Brunet S, Martino R, Sierra J.

Biol Blood Marrow Transplant. 2018 Jan;24(1):55-63. doi: 10.1016/j.bbmt.2017.09.001. Epub 2017 Sep 20.

20.

Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment Outcomes.

Diaz de la Guardia R, Lopez-Millan B, Lavoie JR, Bueno C, Castaño J, Gómez-Casares M, Vives S, Palomo L, Juan M, Delgado J, Blanco ML, Nomdedeu J, Chaparro A, Fuster JL, Anguita E, Rosu-Myles M, Menéndez P.

Stem Cell Reports. 2017 Jun 6;8(6):1573-1586. doi: 10.1016/j.stemcr.2017.04.019. Epub 2017 May 18.

21.

FcγRIIb expression in early stage chronic lymphocytic leukemia.

Bosch R, Mora A, Vicente EP, Ferrer G, Jansà S, Damle R, Gorlatov S, Rai K, Montserrat E, Nomdedeu J, Pratcorona M, Blanco L, Saavedra S, Garrido A, Esquirol A, Garcia I, Granell M, Martino R, Delgado J, Sierra J, Chiorazzi N, Moreno C.

Leuk Lymphoma. 2017 Nov;58(11):2642-2648. doi: 10.1080/10428194.2017.1307981. Epub 2017 Apr 4.

22.

Epigenetic loss of the RNA decapping enzyme NUDT16 mediates C-MYC activation in T-cell acute lymphoblastic leukemia.

Anadón C, van Tetering G, Ferreira HJ, Moutinho C, Martínez-Cardús A, Villanueva A, Soler M, Heyn H, Moran S, Castro de Moura M, Setien F, Vidal A, Genescà E, Ribera JM, Nomdedeu JF, Guil S, Esteller M.

Leukemia. 2017 Jul;31(7):1622-1625. doi: 10.1038/leu.2017.99. Epub 2017 Mar 27. No abstract available.

23.

Erytrocyte-related phenotypes and genetic susceptibility to thrombosis.

Remacha AF, Vilalta N, Sardà MP, Millón J, Pujol-Moix N, Ziyatdinov A, Fontcuberta J, Nomdedeu J, Soria JM, Souto JC.

Blood Cells Mol Dis. 2016 Jul;59:44-8. doi: 10.1016/j.bcmd.2016.04.006. Epub 2016 Apr 13. No abstract available.

PMID:
27282566
24.

Feasibility of the AML profiler (Skyline™ Array) for patient risk stratification in a multicentre trial: a preliminary comparison with the conventional approach.

Nomdedéu JF, Puigdecanet E, Bussaglia E, Hernández JJ, Carricondo M, Estivill C, Martí-Tutusaus JM, Tormo M, Zamora L, Serrano E, Perea G, de Llano MPQ, García A, Sánchez-Ortega I, Ribera JM, Nonell L, Aventin A, Solé F, Brunet MS, Sierra J.

Hematol Oncol. 2017 Dec;35(4):778-788. doi: 10.1002/hon.2304. Epub 2016 May 3.

PMID:
27140599
25.

Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies.

McKerrell T, Moreno T, Ponstingl H, Bolli N, Dias JM, Tischler G, Colonna V, Manasse B, Bench A, Bloxham D, Herman B, Fletcher D, Park N, Quail MA, Manes N, Hodkinson C, Baxter J, Sierra J, Foukaneli T, Warren AJ, Chi J, Costeas P, Rad R, Huntly B, Grove C, Ning Z, Tyler-Smith C, Varela I, Scott M, Nomdedeu J, Mustonen V, Vassiliou GS.

Blood. 2016 Jul 7;128(1):e1-9. doi: 10.1182/blood-2015-11-683334. Epub 2016 Apr 27.

26.

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.

Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, Palacio C, Stehlikova O, Kreuzer KA, Liptrot S, O'Brien D, de Tute RM, Marinov I, Hauwel M, Spacek M, Dobber J, Kater AP, Gambell P, Soosapilla A, Lozanski G, Brachtl G, Lin K, Boysen J, Hanson C, Jorgensen JL, Stetler-Stevenson M, Yuan C, Broome HE, Rassenti L, Craig F, Delgado J, Moreno C, Bosch F, Egle A, Doubek M, Pospisilova S, Mulligan S, Westerman D, Sanders CM, Emerson R, Robins HS, Kirsch I, Shanafelt T, Pettitt A, Kipps TJ, Wierda WG, Cymbalista F, Hallek M, Hillmen P, Montserrat E, Ghia P.

Leukemia. 2016 Apr;30(4):929-36. doi: 10.1038/leu.2015.313. Epub 2015 Dec 7.

27.

The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.

Díaz-Beyá M, Brunet S, Nomdedéu J, Pratcorona M, Cordeiro A, Gallardo D, Escoda L, Tormo M, Heras I, Ribera JM, Duarte R, de Llano MP, Bargay J, Sampol A, Nomdedeu M, Risueño RM, Hoyos M, Sierra J, Monzo M, Navarro A, Esteve J; Cooperative AML group CETLAM.

Oncotarget. 2015 Oct 13;6(31):31613-27. doi: 10.18632/oncotarget.5148.

28.

The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.

Díaz-Beyá M, Brunet S, Nomdedéu J, Cordeiro A, Tormo M, Escoda L, Ribera JM, Arnan M, Heras I, Gallardo D, Bargay J, Queipo de Llano MP, Salamero O, Martí JM, Sampol A, Pedro C, Hoyos M, Pratcorona M, Castellano JJ, Nomdedeu M, Risueño RM, Sierra J, Monzó M, Navarro A, Esteve J.

Blood Cancer J. 2015 Oct 2;5:e352. doi: 10.1038/bcj.2015.76.

29.

Colonoscopy through appendectomy in a colonic stenosis.

Sábado F, Nomdedeu J, Aragó P, Ahicart D, Castelló B, Peris A.

Endoscopy. 2015;47 Suppl 1 UCTN:E415-6. doi: 10.1055/s-0034-1392670. Epub 2015 Sep 23. No abstract available.

PMID:
26397846
30.

Complex measurements may be required to establish the prognostic impact of immunophenotypic markers in AML.

García-Dabrio MC, Hoyos M, Brunet S, Tormo M, Ribera JM, Esteve J, Gallardo D, Duarte RF, de Llano MP, Bargay J, Martí-Tutusaus JM, Heras I, Garcia A, Salamero O, Aventin A, Lecrevisse Q, Orfao A, Sierra J, Nomdedéu JF.

Am J Clin Pathol. 2015 Sep;144(3):484-92. doi: 10.1309/AJCPRL6XSVFMLH9V.

PMID:
26276779
31.

Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols.

Ribera J, Morgades M, Zamora L, Montesinos P, Gómez-Seguí I, Pratcorona M, Sarrà J, Guàrdia R, Nomdedeu J, Tormo M, Martínez-Lopez J, Hernández-Rivas JM, González-Campos J, Barba P, Escoda L, Genescà E, Solé F, Millá F, Feliu E, Ribera JM; Spanish PETHEMA Group and the Spanish Society of Hematology.

Cancer. 2015 Nov 1;121(21):3809-17. doi: 10.1002/cncr.29579. Epub 2015 Jul 20.

32.

Genetic determinants of platelet large-cell ratio, immature platelet fraction, and other platelet-related phenotypes.

Pujol-Moix N, Vázquez-Santiago M, Morera A, Ziyatdinov A, Remacha A, Nomdedeu JF, Fontcuberta J, Soria JM, Souto JC.

Thromb Res. 2015 Aug;136(2):361-6. doi: 10.1016/j.thromres.2015.06.016. Epub 2015 Jun 17.

PMID:
26148565
33.

A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR.

White H, Deprez L, Corbisier P, Hall V, Lin F, Mazoua S, Trapmann S, Aggerholm A, Andrikovics H, Akiki S, Barbany G, Boeckx N, Bench A, Catherwood M, Cayuela JM, Chudleigh S, Clench T, Colomer D, Daraio F, Dulucq S, Farrugia J, Fletcher L, Foroni L, Ganderton R, Gerrard G, Gineikienė E, Hayette S, El Housni H, Izzo B, Jansson M, Johnels P, Jurcek T, Kairisto V, Kizilors A, Kim DW, Lange T, Lion T, Polakova KM, Martinelli G, McCarron S, Merle PA, Milner B, Mitterbauer-Hohendanner G, Nagar M, Nickless G, Nomdedéu J, Nymoen DA, Leibundgut EO, Ozbek U, Pajič T, Pfeifer H, Preudhomme C, Raudsepp K, Romeo G, Sacha T, Talmaci R, Touloumenidou T, Van der Velden VH, Waits P, Wang L, Wilkinson E, Wilson G, Wren D, Zadro R, Ziermann J, Zoi K, Müller MC, Hochhaus A, Schimmel H, Cross NC, Emons H.

Leukemia. 2015 Feb;29(2):369-76. doi: 10.1038/leu.2014.217. Epub 2014 Jul 18.

34.

Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1.

Rozman M, Navarro JT, Arenillas L, Aventín A, Giménez T, Alonso E, Perea G, Camós M, Navarrete M, Tuset E, Florensa L, Millá F, Nomdedéu J, de la Banda E, Díaz-Beyá M, Pratcorona M, Garrido A, Navarro B, Brunet S, Sierra J, Esteve J; Grup Català de Citologia Hematològica and Spanish CETLAM Group (Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas).

Ann Hematol. 2014 Oct;93(10):1695-703. doi: 10.1007/s00277-014-2100-6. Epub 2014 May 14.

PMID:
24824767
35.

MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia.

Díaz-Beyá M, Brunet S, Nomdedéu J, Tejero R, Díaz T, Pratcorona M, Tormo M, Ribera JM, Escoda L, Duarte R, Gallardo D, Heras I, Queipo de Llano MP, Bargay J, Monzo M, Sierra J, Navarro A, Esteve J; Cooperative AML group CETLAM (Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias).

Leukemia. 2014 Apr;28(4):804-12. doi: 10.1038/leu.2013.281. Epub 2013 Sep 27.

PMID:
24072101
36.

Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease.

Hoyos M, Nomdedeu JF, Esteve J, Duarte R, Ribera JM, Llorente A, Escoda L, Bueno J, Tormo M, Gallardo D, de Llano MP, Martí JM, Aventín A, Mangues R, Brunet S, Sierra J.

Eur J Haematol. 2013 Sep;91(3):209-18. doi: 10.1111/ejh.12130. Epub 2013 Jul 25.

PMID:
23646898
37.

Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia.

Rossi D, Spina V, Bomben R, Rasi S, Dal-Bo M, Bruscaggin A, Rossi FM, Monti S, Degan M, Ciardullo C, Serra R, Zucchetto A, Nomdedeu J, Bulian P, Grossi A, Zaja F, Pozzato G, Laurenti L, Efremov DG, Di-Raimondo F, Marasca R, Forconi F, Del Poeta G, Gaidano G, Gattei V.

Blood. 2013 Jun 13;121(24):4902-5. doi: 10.1182/blood-2013-02-486209. Epub 2013 May 1.

38.

Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML.

Nomdedéu JF, Hoyos M, Carricondo M, Bussaglia E, Estivill C, Esteve J, Tormo M, Duarte R, Salamero O, de Llano MP, García A, Bargay J, Heras I, Martí-Tutusaus JM, Llorente A, Ribera JM, Gallardo D, Aventin A, Brunet S, Sierra J; CETLAM Group.

Leukemia. 2013 Nov;27(11):2157-64. doi: 10.1038/leu.2013.111. Epub 2013 Apr 15.

PMID:
23584566
39.

Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy.

Pratcorona M, Brunet S, Nomdedéu J, Ribera JM, Tormo M, Duarte R, Escoda L, Guàrdia R, Queipo de Llano MP, Salamero O, Bargay J, Pedro C, Martí JM, Torrebadell M, Díaz-Beyá M, Camós M, Colomer D, Hoyos M, Sierra J, Esteve J; Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas.

Blood. 2013 Apr 4;121(14):2734-8. doi: 10.1182/blood-2012-06-431122. Epub 2013 Feb 1.

40.

Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia.

Rossi D, Rasi S, Spina V, Bruscaggin A, Monti S, Ciardullo C, Deambrogi C, Khiabanian H, Serra R, Bertoni F, Forconi F, Laurenti L, Marasca R, Dal-Bo M, Rossi FM, Bulian P, Nomdedeu J, Del Poeta G, Gattei V, Pasqualucci L, Rabadan R, Foà R, Dalla-Favera R, Gaidano G.

Blood. 2013 Feb 21;121(8):1403-12. doi: 10.1182/blood-2012-09-458265. Epub 2012 Dec 13.

41.

Genome-wide DNA methylation profiling predicts relapse in childhood B-cell acute lymphoblastic leukaemia.

Sandoval J, Heyn H, Méndez-González J, Gomez A, Moran S, Baiget M, Melo M, Badell I, Nomdedéu JF, Esteller M.

Br J Haematol. 2013 Feb;160(3):406-9. doi: 10.1111/bjh.12113. Epub 2012 Oct 30. No abstract available.

42.

Influence of age, gender and lifestyle in lymphocyte subsets: report from the Spanish Gait-2 Study.

García-Dabrio MC, Pujol-Moix N, Martinez-Perez A, Fontcuberta J, Souto JC, Soria JM, Nomdedéu JF.

Acta Haematol. 2012;127(4):244-9. doi: 10.1159/000337051. Epub 2012 Apr 24.

PMID:
22538526
43.

Adverse impact of IDH1 and IDH2 mutations in primary AML: experience of the Spanish CETLAM group.

Nomdedéu J, Hoyos M, Carricondo M, Esteve J, Bussaglia E, Estivill C, Ribera JM, Duarte R, Salamero O, Gallardo D, Pedro C, Aventin A, Brunet S, Sierra J.

Leuk Res. 2012 Aug;36(8):990-7. doi: 10.1016/j.leukres.2012.03.019. Epub 2012 Apr 19.

PMID:
22520341
44.

Subcutaneous passage increases cell aggressiveness in a xenograft model of diffuse large B cell lymphoma.

Bosch R, Moreno MJ, Dieguez-Gonzalez R, Céspedes MV, Gallardo A, Nomdedeu J, Pavón MA, Espinosa I, Mangues MA, Sierra J, Casanova I, Mangues R.

Clin Exp Metastasis. 2012 Apr;29(4):339-47. doi: 10.1007/s10585-012-9454-8. Epub 2012 Jan 20.

PMID:
22262061
45.

E-box-independent regulation of transcription and differentiation by MYC.

Uribesalgo I, Buschbeck M, Gutiérrez A, Teichmann S, Demajo S, Kuebler B, Nomdedéu JF, Martín-Caballero J, Roma G, Benitah SA, Di Croce L.

Nat Cell Biol. 2011 Oct 23;13(12):1443-9. doi: 10.1038/ncb2355.

PMID:
22020439
46.

Autonomic, neuroendocrine, and immunological effects of ayahuasca: a comparative study with d-amphetamine.

Dos Santos RG, Valle M, Bouso JC, Nomdedéu JF, Rodríguez-Espinosa J, McIlhenny EH, Barker SA, Barbanoj MJ, Riba J.

J Clin Psychopharmacol. 2011 Dec;31(6):717-26. doi: 10.1097/JCP.0b013e31823607f6.

PMID:
22005052
47.

Pharmacology of ayahuasca administered in two repeated doses.

Dos Santos RG, Grasa E, Valle M, Ballester MR, Bouso JC, Nomdedéu JF, Homs R, Barbanoj MJ, Riba J.

Psychopharmacology (Berl). 2012 Feb;219(4):1039-53. doi: 10.1007/s00213-011-2434-x. Epub 2011 Aug 13.

PMID:
21842159
48.

Immunophenotype distinction between acute promyelocytic leukaemia and CD15- CD34- HLA-DR- acute myeloid leukaemia with nucleophosmin mutations.

Ferrari A, Bussaglia E, Úbeda J, Facchini L, Aventin A, Sierra J, Nomdedéu JF.

Hematol Oncol. 2012 Sep;30(3):109-14. doi: 10.1002/hon.1011. Epub 2011 Aug 3.

PMID:
21812014
49.

Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion.

Mian M, Scandurra M, Chigrinova E, Shen Y, Inghirami G, Greiner TC, Chan WC, Vose JM, Testoni M, Chiappella A, Baldini L, Ponzoni M, Ferreri AJ, Franceschetti S, Gaidano G, Montes-Moreno S, Piris MA, Facchetti F, Tucci A, Nomdedeu JF, Lazure T, Uccella S, Tibiletti MG, Zucca E, Kwee I, Bertoni F.

Ann Oncol. 2012 Mar;23(3):729-35. doi: 10.1093/annonc/mdr289. Epub 2011 Jun 21.

PMID:
21693768
50.

Rituximab treatment may disturb the normal pattern of lymphopoiesis after cord blood SCT.

Barba P, Garcia-Cadenas I, Nomdedéu J, Martino R, Gallur L, Valcárcel D.

Bone Marrow Transplant. 2012 Mar;47(3):458-60. doi: 10.1038/bmt.2011.98. Epub 2011 May 9. No abstract available.

PMID:
21552304

Supplemental Content

Loading ...
Support Center